Sirtex and Guerbet Announce Collaboration On Clinical Studies in Liver Cancer

PRINCETON, N.J., March 24, 2014 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are pleased to announce today that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers*.

Sirtex's Chief Medical Officer, David Cade said that "Interventional Oncology is one of the fastest growing and most exciting areas of innovation in cancer care, giving patients with few or no treatment choices, an extended lease on life while helping maintain their quality of life."

"We are looking forward to open new horizons in Interventional Oncology and we are determined to explore a symbiotic clinical research partnership as we relentlessly pursue our goal to help patients with unresectable hepatic tumors," said Guerbet's US General Manager, Massimo Carrara.

Guerbet and Sirtex share a common vision to advance interventional oncology by developing new approaches in patient care and treatment algorithms that may revolutionize liver cancer therapy in the future.

*The scope of collaboration and development activities between Sirtex and Guerbet is currently being finalized, with additional announcements expected to be made in 2014.

About Sirtex

Sirtex is a global life-sciences company that develops and delivers effective oncology treatments using novel small particle technology. Current research involving radio-protector technologies and novel small particle technology are two areas of focus amongst an expanding portfolio of products designed to offer cancer patients treatment options in the management of their disease. Sirtex devotes significant resources to the future growth of the company with approximately 23% of $100 million in sales for 2013 invested in research and development and clinical studies. Sirtex (SRX) is listed on the Australian Stock Exchange. For additional information about Sirtex, please go to www.sirtex.com.

About Guerbet

A pioneer in the field of contrast agents with more than 80 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. As such it has a complete offering of contrast products for X-ray and MRI and for Interventional Radiology, along with a range of injectors and related medical equipment to provide improved diagnosis and treatment of patients. To promote the discovery of new products and assure future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on the NYSE Euronext Paris (Eurolist Segment B – Mid Caps) and had sales of €390 million in 2013 with a total workforce of 1,485 employees. For additional information about Guerbet please go to www.guerbet.com.

This press release may contain forward-looking statements based on current assumptions and forecasts made by Sirtex and Guerbet management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performances of the company and the estimates given here. These factors include those discussed in Sirtex and Guerbet's public reports which are available on the Sirtex and Guerbet websites at www.sirtex.com and www.guerbet.com. The companies assume no liability whatsoever to update these forward-looking-statements or to conform them to future events or developments.

SOURCE Guerbet S.A.